세계의 RS 바이러스(RSV) 치료 시장 : 약제 유형별, 제형별, 지역별 - 시장 규모, 산업 역학, 기회 분석, 예측(2025-2033년)

The global respiratory syncytial virus (RSV) treatment market is experiencing rapid and substantial growth, reflecting the increasing recognition of RSV as a major public health challenge worldwide. Valued at approximately USD 2,387.2 million in 2024, the market is projected to expand significantly over the coming decade, reaching an estimated USD 8,332.5 million by 2033. This impressive growth corresponds to a compound annual growth rate (CAGR) of 14.9% during the forecast period. Several factors are driving this expansion, including the rising adoption of RSV vaccines, enhancements in diagnostic infrastructure, and growing public and clinical awareness of the disease.

North America currently leads the global RSV treatment market, benefiting from a combination of early vaccine approvals, substantial funding for research and development, and a well-established healthcare infrastructure capable of supporting widespread disease management and prevention efforts. In the United States specifically, RSV continues to pose a significant health concern, particularly for vulnerable populations such as infants and the elderly. According to estimates from the Centers for Disease Control and Prevention (CDC) in 2024, RSV was responsible for between 3.6 and 6.5 million outpatient visits, 190,000 to 350,000 hospitalizations, and up to 23,000 deaths annually. These staggering figures underscore the critical need for effective prevention and treatment strategies.

Noteworthy Market Developments

Several prominent pharmaceutical and biotechnology companies are actively driving innovation in the respiratory syncytial virus (RSV) vaccine market, reflecting the growing importance of effective RSV prevention strategies. Leading players such as Moderna, Sanofi, GSK, AstraZeneca, Pfizer, Enanta Pharmaceuticals, Bavarian Nordic, Novavax, and BlueWillow Biologics are at the forefront of developing new vaccines and advancing clinical research to address the unmet needs in RSV protection across different age groups.

A notable example of recent progress is Pfizer's ABRYSVO, which received approval from the European Union on April 1, 2025, for use in adults aged 18 to 59 years with lower respiratory tract disease. This approval was supported by data from the Phase 3 MONet trial (NCT05842967), which demonstrated that ABRYSVO has a strong safety profile, is well tolerated, and elicits a robust immune response. With this regulatory milestone, ABRYSVO has become the vaccine offering the broadest RSV protection in the EU, covering adults 18 years and older as well as infants up to six months of age through maternal immunization.

In addition to Pfizer's advances, Clover Biopharmaceuticals has also made significant strides in the RSV vaccine field. On March 23, 2025, Clover received clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase I clinical trial for its candidate vaccine SCB-1019. This trial is designed specifically to evaluate the booster efficacy of SCB-1019 in older adults who have previously been vaccinated with GSK's AREXVY, an RSV vaccine already approved for this population.

Core Growth Drivers

Respiratory syncytial virus (RSV) remains a major global health challenge, with a particularly profound impact on infants and young children. This virus is one of the leading causes of lower respiratory tract infections in this vulnerable population, often resulting in severe illness that necessitates medical intervention. In the United States alone, RSV is responsible for an estimated 2.1 million outpatient visits annually among children under the age of five, highlighting the widespread nature of the infection.

Hospitalizations due to RSV also represent a critical aspect of this burden, with between 58,000 and 80,000 children under five admitted to hospitals each year in the U.S. alone. These hospital stays are often required for cases involving severe respiratory distress or complications, such as bronchiolitis or pneumonia, which demand close monitoring and supportive care. The high number of hospital admissions not only reflects the severity of RSV infections in young children but also contributes to increased healthcare costs and resource utilization.

Emerging Opportunity Trends

The rollout of respiratory syncytial virus (RSV) vaccines represents a major advancement in the prevention of respiratory diseases, marking a significant milestone in public health efforts to protect vulnerable populations, especially infants and the elderly. These vaccines have proven effective in reducing the incidence and severity of RSV infections, which historically have posed a serious threat due to limited preventive options. Their introduction has not only improved clinical outcomes but also paved the way for innovative approaches to respiratory disease management.

Building on the success of recent RSV vaccine launches, pharmaceutical companies such as AstraZeneca and Moderna are actively developing next-generation vaccines that combine RSV protection with immunization against other significant respiratory illnesses. These combination vaccines aim to streamline immunization schedules, enhance patient compliance, and provide comprehensive protection by targeting multiple viruses simultaneously.

Barriers to Optimization

Respiratory syncytial virus (RSV) disease represents a significant health burden, particularly in low- and middle-income countries (LMICs), where it is a leading cause of severe respiratory illness and mortality among infants and young children. In these regions, the impact of RSV is particularly devastating due to limited access to healthcare resources, insufficient infrastructure, and the vulnerability of young populations.

The virus contributes to high rates of hospitalization and long-term respiratory complications, placing immense strain on families and healthcare systems already stretched thin by other public health challenges. Addressing RSV in LMICs is therefore a critical priority for reducing childhood morbidity and mortality. For example, recently approved drugs such as Beyfortus and Abrysvo, which offer promising protection against RSV, are priced at levels that are prohibitive for many families and healthcare providers operating within constrained budgets. Beyfortus, priced at approximately USD 414.75 per dose, and Abrysvo, costing around USD 230.00 per dose

Detailed Market Segmentation

By Dosage Form, injectables currently dominate the dosage form segment, holding an overwhelming market share exceeding 85%. This dominance reflects a strong preference within the medical community and patients for injectable therapies, which are widely recognized for their rapid onset of action and high clinical efficacy. The growing acceptance and utilization of vaccines and monoclonal antibodies (mAbs) have been significant drivers behind this trend.

By Drug Type, vaccines hold a dominant position in the drug market, commanding over 50% of the total market share. This leadership is largely driven by the recent approvals of new vaccines and their expanding application across a broader range of age groups, from infants and children to adults and the elderly. The growing awareness of preventive healthcare, coupled with increased public health initiatives and vaccination campaigns, has significantly boosted demand for vaccines worldwide. As a result, this segment has experienced robust growth, becoming a major contributor to the overall market.

Segment Breakdown

By Drug Type

• Vaccines
  • Abrysvo
  • Arexvy
  • MRESVIA
• Monoclonal Antibodies
  • Synagis
  • Beyfortus
• Antivirals

By Dosage Forms

• Injectables
• Orals
• Antivirals

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America

Leading Market Participants

• Moderna
• Sanofi
• GSK
• AstraZeneca
• Pfizer
• Enanta Pharmaceuticals, Inc
• Bavarian Nordic
• Novavax
• BlueWillow Biologics
• Other Prominent Players

Table of Content

Chapter 1. Research Framework

• 1.1. Objective
• 1.2. Product Overview
  • 1.2.1. Market Segmentation
  • 1.2.2. Market & Segment Definitions
• 1.3. Research Methodology
  • 1.3.1. List of Primary & Secondary Sources
  • 1.3.2. Market Size Estimation
    • 1.3.2.1. Assumption for the Study
    • 1.3.2.2. Data Triangulation

Chapter 3. Global Respiratory Syncytial Virus Treatment Market Overview

• 3.1. Industry Value Chain Analysis
  • 3.1.1. Research and Formulation
  • 3.1.2. Development and Packaging
  • 3.1.3. Sales and Distribution
  • 3.1.4. End Users
• 3.2. Industry Outlook
  • 3.2.1. Epidemiology and Patient Population
    • 3.2.1.1. Key Findings
    • 3.2.1.2. Epidem and Market Methodology
    • 3.2.1.3. 8MM Incident Patient Population of Respiratory Syncytial Virus Treatment
  • 3.2.2. Country Wise-Epidemiology of Respiratory Syncytial Virus Treatment
    • 3.2.2.1. United States Epidemiology
      • 3.2.2.1.1. Assumptions and Rationale
      • 3.2.2.1.2. Total Incident Cases of Respiratory Syncytial Virus Treatment in the United States
      • 3.2.2.1.3. Case-Specific Incidence of Respiratory Syncytial Virus Treatment in the United States
      • 3.2.2.1.4. Age-Specific Incidence of Respiratory Syncytial Virus Treatment in United States
      • 3.2.2.1.5. Incidence of Respiratory Syncytial Virus Treatment by Extremities (%) in the United States
    • 3.2.2.2. EU5 Epidemiology
      • 3.2.2.2.1. Germany
        • 3.2.2.2.1.1. Assumptions and Rationale
        • 3.2.2.2.1.2. Total Incident Cases of Respiratory Syncytial Virus Treatment in the Germany
        • 3.2.2.2.1.3. Case-Specific Incidence of Respiratory Syncytial Virus Treatment in the Germany
        • 3.2.2.2.1.4. Age-Specific Incidence of Respiratory Syncytial Virus Treatment in Germany
        • 3.2.2.2.1.5. Incidence of Respiratory Syncytial Virus Treatment by Extremities (%) in the Germany
      • 3.2.2.2.2. France
        • 3.2.2.2.2.1. Assumptions and Rationale
        • 3.2.2.2.2.2. Total Incident Cases of Respiratory Syncytial Virus Treatment in the France
        • 3.2.2.2.2.3. Case-Specific Incidence of Respiratory Syncytial Virus Treatment in the France
        • 3.2.2.2.2.4. Age-Specific Incidence of Respiratory Syncytial Virus Treatment in France
        • 3.2.2.2.2.5. Incidence of Respiratory Syncytial Virus Treatment by Extremities (%) in the France
      • 3.2.2.2.3. Italy
        • 3.2.2.2.3.1. Assumptions and Rationale
        • 3.2.2.2.3.2. Total Incident Cases of Respiratory Syncytial Virus Treatment in the Italy
        • 3.2.2.2.3.3. Case-Specific Incidence of Respiratory Syncytial Virus Treatment in the Italy
        • 3.2.2.2.3.4. Age-Specific Incidence of Respiratory Syncytial Virus Treatment in Italy
        • 3.2.2.2.3.5. Incidence of Respiratory Syncytial Virus Treatment by Extremities (%) in the Italy
      • 3.2.2.2.4. Spain
        • 3.2.2.2.4.1. Assumptions and Rationale
        • 3.2.2.2.4.2. Total Incident Cases of Respiratory Syncytial Virus Treatment in the Spain
        • 3.2.2.2.4.3. Case-Specific Incidence of Respiratory Syncytial Virus Treatment in the Spain
        • 3.2.2.2.4.4. Age-Specific Incidence of Respiratory Syncytial Virus Treatment in Spain
        • 3.2.2.2.4.5. Incidence of Respiratory Syncytial Virus Treatment by Extremities (%) in the Spain
      • 3.2.2.2.5. United Kingdom
        • 3.2.2.2.5.1. Assumptions and Rationale
        • 3.2.2.2.5.2. Total Incident Cases of Respiratory Syncytial Virus Treatment in the UK
        • 3.2.2.2.5.3. Case-Specific Incidence of Respiratory Syncytial Virus Treatment in the UK
        • 3.2.2.2.5.4. Age-Specific Incidence of Respiratory Syncytial Virus Treatment in UK
        • 3.2.2.2.5.5. Incidence of Respiratory Syncytial Virus Treatment by Extremities (%) in the UK
    • 3.2.2.3. Japan Epidemiology
      • 3.2.2.3.1. Assumptions and Rationale
      • 3.2.2.3.2. Total Incident Cases of Respiratory Syncytial Virus Treatment in the Japan
      • 3.2.2.3.3. Case-Specific Incidence of Respiratory Syncytial Virus Treatment in the Japan
      • 3.2.2.3.4. Age-Specific Incidence of Respiratory Syncytial Virus Treatment in Japan
      • 3.2.2.3.5. Incidence of Respiratory Syncytial Virus Treatment by Extremities (%) in the Japan
    • 3.2.2.4. China Epidemiology
      • 3.2.2.4.1. Assumptions and Rationale
      • 3.2.2.4.2. Total Incident Cases of Respiratory Syncytial Virus Treatment in the China
      • 3.2.2.4.3. Case-Specific Incidence of Respiratory Syncytial Virus Treatment in the China
      • 3.2.2.4.4. Age-Specific Incidence of Respiratory Syncytial Virus Treatment in China
      • 3.2.2.4.5. Incidence of Respiratory Syncytial Virus Treatment by Extremities (%) in the China
    • 3.2.2.5. India Epidemiology
      • 3.2.2.5.1. Assumptions and Rationale
      • 3.2.2.5.2. Total Incident Cases of Respiratory Syncytial Virus Treatment in the India
      • 3.2.2.5.3. Case-Specific Incidence of Respiratory Syncytial Virus Treatment in the India
      • 3.2.2.5.4. Age-Specific Incidence of Respiratory Syncytial Virus Treatment in India
      • 3.2.2.5.5. Incidence of Respiratory Syncytial Virus Treatment by Extremities (%) in the India
  • 3.2.3. Treatment and Management of Respiratory Syncytial Virus Treatment
    • 3.2.3.1. Scope of Treatment
    • 3.2.3.2. Treatment Guidelines
    • 3.2.3.3. American Academy of Pediatrics guidelines for Respiratory Syncytial Virus Treatment
  • 3.2.4. Unmet Needs
  • 3.2.5. Marketed Drugs
    • 3.2.5.1. Synagis (Palivizumab): MedImmune/Abbott Laboratories Inc.
      • 3.2.5.1.1. Product Description
      • 3.2.5.1.2. Regulatory Milestones
      • 3.2.5.1.3. Clinical Development
      • 3.2.5.1.4. Ongoing Current Pipeline Activity
      • 3.2.5.1.5. Safety and efficacy
      • 3.2.5.1.6. Product Profile
    • 3.2.5.2. Virazole (Ribavirin): ICN Pharmaceuticals
      • 3.2.5.2.1. Product Description
      • 3.2.5.2.2. Regulatory Milestones
      • 3.2.5.2.3. Clinical Development
      • 3.2.5.2.4. Ongoing Current Pipeline Activity
      • 3.2.5.2.5. Safety and efficacy
      • 3.2.5.2.6. Product Profile
  • 3.2.6. Emerging Drugs
    • 3.2.6.1. EDP 938: Enanta Pharmaceuticals
      • 3.2.6.1.1. Product Description
      • 3.2.6.1.2. Other Development Activities
      • 3.2.6.1.3. Clinical Development
      • 3.2.6.1.4. Clinical Trials Information
      • 3.2.6.1.5. Safety and Efficacy
      • 3.2.6.1.6. Product Profile
    • 3.2.6.2. Nirsevimab: AstraZeneca
      • 3.2.6.2.1. Product Description
      • 3.2.6.2.2. Other Development Activities
      • 3.2.6.2.3. Clinical Development
      • 3.2.6.2.4. Clinical Trials Information
      • 3.2.6.2.5. Safety and Efficacy
      • 3.2.6.2.6. Product Profile
    • 3.2.6.3. MEDI8897: MedImmune LLC
      • 3.2.6.3.1. Product Description
      • 3.2.6.3.2. Other Development Activities
      • 3.2.6.3.3. Clinical Development
      • 3.2.6.3.4. Clinical Trials Information
      • 3.2.6.3.5. Safety and Efficacy
      • 3.2.6.3.6. Product Profile
    • 3.2.6.4. JNJ-53718678: Janssen Sciences Ireland UC
      • 3.2.6.4.1. Product Description
      • 3.2.6.4.2. Other Development Activities
      • 3.2.6.4.3. Clinical Development
      • 3.2.6.4.4. Clinical Trials Information
      • 3.2.6.4.5. Safety and Efficacy
      • 3.2.6.4.6. Product Profile
  • 3.2.7. Target population and RSV vaccine
    • 3.2.7.1. Maternal
    • 3.2.7.2. Infants
    • 3.2.7.3. Children
    • 3.2.7.4. Elderly
  • 3.2.8. RSV Vaccines in pipeline
• 3.3. PESTLE Analysis
• 3.4. Porter's Five Forces Analysis
  • 3.4.1. Bargaining Power of Suppliers
  • 3.4.2. Bargaining Power of Buyers
  • 3.4.3. Threat of Substitutes
  • 3.4.4. Threat of New Entrants
  • 3.4.5. Degree of Competition
• 3.5. Market Dynamics and Trends
  • 3.5.1. Key Trends
  • 3.5.2. Growth Drivers
  • 3.5.3. Restraints/ Challenges
• 3.6. Market Growth and Outlook
  • 3.6.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2033
  • 3.6.2. Pricing Analysis
• 3.7. Covid-19 Impact Assessment on Market Growth Trend
  • 3.7.1. Growth Trend Shift Analysis
  • 3.7.2. Industry Best Practices
• 3.8. Regulatory Landscape

Chapter 4. Competition Dashboard

• 4.1. Market Concentration Rate
• 4.2. Company Market Share Analysis (Value %), 2024
• 4.3. Competitor Mappin

Chapter 5. Respiratory Syncytial Virus Treatment Market Analysis, By Drug type

• 5.1. Key Insights
• 5.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
  • 5.2.1. Ribavirin
  • 5.2.2. Synagis
  • 5.2.3. Virazole
  • 5.2.4. Palivizumab
  • 5.2.5. Riba Tab
  • 5.2.6. Others

Chapter 6. Respiratory Syncytial Virus Treatment Market Analysis, By Dosage Form

• 6.1. Key Insights
• 6.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
  • 6.2.1. Oral
  • 6.2.2. Injectable
  • 6.2.3. Inhaler
  • 6.2.4. Others

Chapter 7. Respiratory Syncytial Virus Treatment Market Analysis, By Treatment Type

• 7.1. Key Insights
• 7.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
  • 7.2.1. Immune prophylaxis
  • 7.2.2. Supportive care
  • 7.2.3. Antiviral Medications

Chapter 8. Respiratory Syncytial Virus Treatment Market Analysis, By Distribution Channel

• 8.1. Key Insights
• 8.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
  • 8.2.1. Hospital pharmacies
  • 8.2.2. Drug Stores
  • 8.2.3. Retail pharmacies
  • 8.2.4. Clinics

Chapter 9. Respiratory Syncytial Virus Treatment Market Analysis, By Region/Country

• 9.1. Key Insights
• 9.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
  • 9.2.1. North America
    • 9.2.1.1. The U.S.
    • 9.2.1.2. Canada
    • 9.2.1.3. Mexico
  • 9.2.2. Europe
    • 9.2.2.1. The UK
    • 9.2.2.2. Germany
    • 9.2.2.3. France
    • 9.2.2.4. Italy
    • 9.2.2.5. Spain
    • 9.2.2.6. Poland
    • 9.2.2.7. Russia
    • 9.2.2.8. Rest of Europe
  • 9.2.3. Asia Pacific
    • 9.2.3.1. China
    • 9.2.3.2. India
    • 9.2.3.3. Japan
    • 9.2.3.4. Australia & New Zealand
    • 9.2.3.5. ASEAN
    • 9.2.3.6. Rest of Asia Pacific
  • 9.2.4. Middle East & Africa
    • 9.2.4.1. UAE
    • 9.2.4.2. Saudi Arabia
    • 9.2.4.3. South Africa
    • 9.2.4.4. Rest of MEA
  • 9.2.5. South America
    • 9.2.5.1. Argentina
    • 9.2.5.2. Brazil
    • 9.2.5.3. Rest of South America

Chapter 10. North America Respiratory Syncytial Virus Treatment Market Analysis

• 10.1. Key Insights
• 10.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
  • 10.2.1. By Drug type
  • 10.2.2. By Dosage form
  • 10.2.3. By Treatment type
  • 10.2.4. By Distribution channel
  • 10.2.5. By Country

Chapter 11. Europe Respiratory Syncytial Virus Treatment Market Analysis

• 11.1. Key Insights
• 11.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)11.2.1. By Drug type
  • 11.2.2. By Dosage form
  • 11.2.3. By Treatment type
  • 11.2.4. By Distribution channel
  • 11.2.5. By Country

Chapter 12. Asia Pacific Respiratory Syncytial Virus Treatment Market Analysis

• 12.1. Key Insights
• 12.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
  • 12.2.1. By Drug type
  • 12.2.2. By Dosage form
  • 12.2.3. By Treatment type
  • 12.2.4. By Distribution channel
  • 12.2.5. By Country

Chapter 13. Middle East & Africa Respiratory Syncytial Virus Treatment Market Analysis

• 13.1. Key Insights
• 13.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
  • 13.2.1. By Drug type
  • 13.2.2. By Dosage form
  • 13.2.3. By Treatment type
  • 13.2.4. By Distribution channel
  • 13.2.5. By Country

Chapter 14. South America Respiratory Syncytial Virus Treatment Market Analysis

• 14.1. Key Insights
• 14.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
  • 14.2.1. By Drug type
  • 14.2.2. By Dosage form
  • 14.2.3. By Treatment type
  • 14.2.4. By Distribution channel
  • 14.2.5. By Country

Chapter 15. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

• 15.1. AbbVie, Inc.
• 15.2. AstraZeneca PLC
• 15.3. Atea Pharmaceuticals
• 15.4. Bausch Health Companies Inc.
• 15.5. Celltrion Inc.
• 15.6. Enanta Pharmaceuticals, Inc
• 15.7. F. Hoffmann-La Roche AG
• 15.8. Gilead Sciences, Inc.
• 15.9. GlaxoSmithKline PLC
• 15.10. Johnson & Johnson's
• 15.11. mAbxience
• 15.12. Medivir AB
• 15.13. Merck Co., Inc.
• 15.14. Pfizer Inc.
• 15.15. ReViral Ltd.
• 15.16. Sanofi
• 15.17. Teva Pharmaceutical Industries Ltd.
• 15.18. Other players